Skip to main content

. 1992 Nov;66(5):875–876. doi: 10.1038/bjc.1992.377

CA-125 is not a useful marker in metastatic breast cancer.

M J Seckl ¹, G J Rustin ¹, R C Coombes ¹

PMCID: PMC1977992 PMID: 1419631

875

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
Beastall G. H., Cook B., Rustin G. J., Jennings J. A review of the role of established tumour markers. Ann Clin Biochem. 1991 Jan;28(Pt 1):5–18. doi: 10.1177/000456329102800102. [DOI] [PubMed] [Google Scholar]
Kawahara M., Terasaki P. I., Chia D., Johnson C., Hermes M., Tokita K. Use of four monoclonal antibodies to detect tumor markers. Cancer. 1986 Nov 1;58(9):2008–2012. doi: 10.1002/1097-0142(19861101)58:9<2008::aid-cncr2820580909>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
Perey L., Hayes D. F., Tondini C., van Melle G., Bauer J., Lemarchand T., Reymond M., Mach J. P., Leyvraz S. Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer. 1990 Oct;62(4):668–670. doi: 10.1038/bjc.1990.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rustin G. J., Nelstrop A., Stilwell J., Lambert H. E. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer. 1992;28(1):79–82. doi: 10.1016/0959-8049(92)90390-n. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES